ACTA2 and breast carcinoma: Acta2-Cre and Acta2-Cre–ERT can be used, but they will also drive recombination in smooth muscle cells and myoepithelial cells, which poses a particular challenge in mouse models of breast cancer, which has a high frequency of these cell types in the tumour microenvironment.